Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gaps in atopic dermatitis management for various patient subgroups.

Michael Lewitt, MD, discusses a case involving a 7-year-old girl with plaque psoriasis (PsO) affecting body surface area (BSA) and the face, emphasizing the limited pediatric treatment options and the psychological and social impact on the child; the family initially opted for topical treatments like roflumilast, but preferred a more proactive approach, transitioning to apremilast while addressing concerns about gastrointestinal adverse events and the patient’s aversion to needles.

Michael Lewitt, MD, discusses a case involving a 55-year-old man with psoriasis (PsO) and psoriatic arthritis (PsA), highlighting challenges such as treatment for sensitive areas like the palms, soles, and scalp, mild morning stiffness, and the patient’s dissatisfaction with prior topical treatments; the discussion includes systemic and topical steroid use, concerns about TNF inhibitors, the effectiveness of phototherapy on limited areas, and the potential adverse events associated with the apremilast standard dose regimen, with phototherapy considered as a rescue option for flares.

Michael Lewitt, MD, provides an overview of Case-Based Roundtable and introduces a case involving a patient with a 10-year history of plaque psoriasis (PsO) in sensitive areas, discussing the significant impact on quality of life, the patient’s aversion to needles as a new mom, and the exploration of biologic therapies as a treatment option.

Panelists discuss how a multidisciplinary approach involving dermatologists, surgeons, radiation oncologists, and medical oncologists is crucial for optimal decision-making and management of complex basal cell carcinoma (BCC) cases, ensuring comprehensive care and improved patient outcomes.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Monica Boen, MD, discusses how implementing proven photodynamic therapy techniques and adhering to best practices can significantly improve treatment outcomes and patient satisfaction.

Monica Boen, MD, discusses how optimizing photodynamic therapy protocols and streamlining patient scheduling can enhance treatment efficiency and maintain steady patient flow in clinical settings.

Panelists discuss how advanced basal cell carcinoma (BCC) presents unique treatment challenges and examine recent developments that show promise for improving outcomes in patients with this aggressive form of skin cancer.

Monica Boen, MD, discusses how analyzing seasonal trends in photodynamic therapy usage and effectiveness can improve treatment planning and patient outcomes.

Delve into the complexities of generalized pustular psoriasis (GPP), a rare and life-threatening skin condition, and explore how the monoclonal antibody spesolimab is being investigated to prevent severe, unpredictable flares.

Ted Lain, MD, MBA, FAAD, discusses how selecting the optimal photodynamic therapy approach involves considering factors such as the specific disease characteristics, patient conditions, available photosensitizers, light sources, and potential combinations with other treatments to maximize efficacy and minimize adverse effects.

Ted Lain, MD, MBA, FAAD, discusses how combining photodynamic therapy with other treatment modalities can potentially enhance therapeutic outcomes, reduce adverse effects, and overcome resistance mechanisms in various diseases, particularly in cancer treatment.

Explore the groundbreaking findings from the Effisayil 2 trial on the efficacy and safety of subcutaneous spesolimab in preventing flares of generalized pustular psoriasis.

Ted Lain, MD, MBA, FAAD, discusses how a combination approach in photodynamic therapy integrates multiple treatment modalities or agents to enhance therapeutic efficacy and overcome limitations of standalone photodynamic treatments for various cancers and other diseases.

Anthony M. Rossi, MD, shares their perspective on the future evolution of photodynamic therapy (PDT) in dermatology practices and discusses emerging data or studies that will be crucial for dermatologists to stay informed about.

Anthony M. Rossi, MD, highlights a successful case of photodynamic therapy (PDT), provides background on the patient’s outcome, and explains how increased use of PDT can enhance patient satisfaction and improve practice outcomes.

Anthony M. Rossi, MD, discusses common barriers to implementing photodynamic therapy (PDT), and provides solutions to specific challenges in the treatment setting.